Preclinical safety evaluation of DNA vaccines encoding modified HPV16 E6 and E7

详细信息	查看全文 | 推荐本文 |

• 作者：F.E. Henken^a ; ¹ ; K. Oosterhuis^b ; ¹ ; P. Ö ; hlschlä ; ger^c ; L. Bosch^a ; E. Hooijberg^a ; J.B.A.G. Haanen^b ; R.D.M. Steenbergen^a ; ^{r.steenbergen@vumc.nl}
• 关键词：HFK ; human foreskin keratinocyte ; HPV ; human papillomavirus ; hr ; high-risk ; PD ; population doubling ; SH ; shuffled ; TTFC ; tetanus toxin fragment C domain 1 ; WT ; wild-type
• 刊名：Vaccine
• 出版年：2012
• 期刊代码：89_0264410x
• 类别：imm
• 出版时间：13 June, 2012
• 卷：30
• 期：28
• 页码：4259-4266
• 文件大小：771 K

摘要

Persistent infection with high-risk human papillomaviruses (hrHPV) can result in the formation of anogenital cancers. As hrHPV proteins E6 and E7 are required for cancer initiation and maintenance, they are ideal targets for immunotherapeutic interventions. Previously, we have described the development of DNA vaccines for the induction of HPV16 E6 and E7 specific T cell immunity. These vaccines consist of 鈥榞ene-shuffled鈥?(SH) versions of HPV16 E6 and E7 that were fused to Tetanus Toxin Fragment C domain 1 (TTFC) and were named TTFC-E6SH and TTFC-E7SH. Gene-shuffling was performed to avoid the risk of inducing malignant transformation at the vaccination site. Here, we describe the preclinical safety evaluation of these candidate vaccines by analysis of their transforming capacity in vitro using established murine fibroblasts (NIH 3T3 cells) and primary human foreskin keratinocytes (HFKs). We demonstrate that neither ectopic expression of TTFC-E6SH and TTFC-E7SH alone or in combination enabled NIH 3T3 cells to form colonies in soft agar. In contrast, expression of HPV16 E6WT and E7WT alone or in combination resulted in effective transformation. Similarly, retroviral transduction of HFKs from three independent donors with both TTFC-E6SH and TTFC-E7SH alone or in combination did not show any signs of immortalization. In contrast, the combined expression of E6WT and E7WT induced immortalization in HFKs from all donors. Based on these results we consider it justified to proceed to clinical evaluation of DNA vaccines encoding TTFC-E6SH and TTFC-E7SH in patients with HPV16 associated (pre)malignancies.